Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for Refractory/Resistant CMV
NCT03728426Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letermovir in cytomegalovirus infection (CMV). Primary endpoint: Virological Response on Treatment Week 6. Started Jan 2019; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03728426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728426.